aTyr Pharma, Inc.
ATYR
$0.58
$0.024.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 190.00K | 190.00K | 190.00K | 190.00K | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 190.00K | 190.00K | 190.00K | 190.00K | 0.00 |
| Cost of Revenue | 40.60M | 40.66M | 45.16M | 46.50M | 39.17M |
| Gross Profit | -40.41M | -40.47M | -44.97M | -46.31M | -39.17M |
| SG&A Expenses | 16.96M | 17.76M | 17.60M | 17.29M | 15.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.05M | 73.48M | 77.82M | 78.84M | 70.05M |
| Operating Income | -63.86M | -73.29M | -77.63M | -78.65M | -70.05M |
| Income Before Tax | -60.81M | -70.03M | -74.12M | -75.13M | -66.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -60.81 | -70.03 | -74.12 | -75.13 | -66.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 5.00K | 5.00K | 5.00K | 5.00K | 5.00K |
| Net Income | -60.81M | -70.03M | -74.12M | -75.12M | -66.64M |
| EBIT | -63.86M | -73.29M | -77.63M | -78.65M | -70.05M |
| EBITDA | -63.20M | -72.63M | -76.96M | -77.98M | -69.36M |
| EPS Basic | -0.62 | -0.73 | -0.80 | -0.83 | -0.80 |
| Normalized Basic EPS | -0.39 | -0.46 | -0.50 | -0.52 | -0.50 |
| EPS Diluted | -0.62 | -0.73 | -0.80 | -0.83 | -0.80 |
| Normalized Diluted EPS | -0.39 | -0.46 | -0.50 | -0.52 | -0.50 |
| Average Basic Shares Outstanding | 391.28M | 383.33M | 371.77M | 356.48M | 335.13M |
| Average Diluted Shares Outstanding | 391.28M | 383.33M | 371.77M | 356.48M | 335.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |